HEPATIC STEATOSIS
Clinical trials for HEPATIC STEATOSIS explained in plain language.
Never miss a new study
Get alerted when new HEPATIC STEATOSIS trials appear
Sign up with your email to follow new studies for HEPATIC STEATOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a probiotic supplement help reverse fatty liver?
Disease control CompletedThis study tests whether a daily probiotic lysate supplement can reduce fat and stiffness in the liver of adults with non-alcoholic fatty liver disease (NAFLD). Participants take either the supplement or a placebo for three months, and doctors measure changes using MRI and ultras…
Matched conditions: HEPATIC STEATOSIS
Phase: NA • Sponsor: Bogomolets National Medical University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could a probiotic supplement help reverse fatty liver?
Disease control CompletedThis study tests whether a daily capsule containing fragments of a probiotic bacterium (L. rhamnosus) can reduce liver fat and improve blood markers in adults with metabolic dysfunction-associated steatotic liver disease (MASLD). Participants take either the supplement or a place…
Matched conditions: HEPATIC STEATOSIS
Phase: NA • Sponsor: Bogomolets National Medical University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New weekly shot aims to tackle fatty liver and obesity
Disease control CompletedThis early-stage trial tested an experimental drug called BI 3006337 in 64 adults who are overweight or obese and have fatty liver disease. Participants received weekly injections of either the drug or a placebo for about 4 months. The main goal was to check safety and tolerabili…
Matched conditions: HEPATIC STEATOSIS
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Timing your meals and exercise may shrink fatty liver
Disease control CompletedThis study looked at whether eating only during a set window each day (time-restricted eating) combined with supervised exercise can reduce fat in the liver and improve heart health in adults with obesity. 187 people took part. The goal was to see if the combination works better …
Matched conditions: HEPATIC STEATOSIS
Phase: NA • Sponsor: Universidad de Granada • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New models aim to predict liver disease in HIV patients
Knowledge-focused CompletedThis study looked at 315 HIV-positive adults to build models that predict fatty liver disease and liver scarring. Researchers used ultrasound and FibroScan tests to track liver changes over time. The goal was to better understand and identify liver problems early in people living…
Matched conditions: HEPATIC STEATOSIS
Sponsor: Shanghai Public Health Clinical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Hormone therapy may improve fatty liver in menopause, small study suggests
Knowledge-focused CompletedThis study examined whether menopausal hormone therapy (MHT) can improve liver function and reduce fat buildup in the liver in postmenopausal women. 44 women were split into two groups: 22 received MHT and 22 did not. After 6 months, researchers measured liver enzymes, fat levels…
Matched conditions: HEPATIC STEATOSIS
Phase: NA • Sponsor: Ipek B. Ozcivit Erkan, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Teens' liver health after weight-loss surgery: a closer look
Knowledge-focused CompletedThis study looked at 20 teens aged 13-20 with severe obesity who were scheduled for bariatric surgery. Researchers measured liver fat and how the body processes energy before and one year after surgery. The goal was to understand how the surgery affects liver health and metabolis…
Matched conditions: HEPATIC STEATOSIS
Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
New fatty liver drug tested in humans for first time
Knowledge-focused CompletedThis early-stage study tested a new medicine called NNC0581-0001 in 48 adults, including healthy volunteers and people with fatty liver (hepatic steatosis). The main goal was to check safety and how the drug moves through the body after a single injection under the skin. Particip…
Matched conditions: HEPATIC STEATOSIS
Phase: PHASE1 • Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC